Why the study?
Do low-dose ENaC blockers (amiloride, triamterene) reduce blood pressure when added as a second-line therapy in patients with primary hypertension?
Population
496 participants with primary hypertension across 6 trials, with a baseline BP of 151/102 mm Hg.
Comparison
Low doses of amiloride and triamterene added as… vs Respective monotherapy (without an ENaC blocker).
Design
Systematic_review, Randomized controlled trials, Double-blind
Follow-up
3 to 12 weeks
Authors
Loading...
Low-dose ENaC blockers should not be added for BP control; confirms lack of clinically meaningful effect as second-line therapy.
Do low-dose ENaC blockers (amiloride, triamterene) reduce blood pressure when added as a second-line therapy in patients with primary hypertension?
Low-dose ENaC blockers do not have a clinically significant blood pressure lowering effect when used as second-line therapy for primary hypertension.
Heran et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: